Reevaluation of the Bicycle Ergometry in the Diagnosis of Ischemic Heart Disease ================================================================================ * Basheer Abdullah Marzoog * Peter Chomakhidze * Philipp Kopylov ## Abstract **Background** Ischemic heart disease (IHD) and related complications and outcomes remain the most frequently reported cardiovascular events. However, the diagnosis and prevention of ischemic heart disease primary depends on the clinical manifestations and electrocardiography changes. **Objectives** Patients with IHD are victims of the poor diagnostic methods and the prevention strategies. **Aims** To assess the diagnostic accuracy of the used bicycle ergometry in the diagnosis of ischemic heart disease based on the results of the stress computed myocardial perfusion (CTP) imaging with vasodilator test (adenosine triphosphate). **Materials and methods** A single center prospective, and non-randomized study included participations aged ≥ 40. The study included 38 participants with vs without IHD confirmed by CTP. The participants done bicycle ergometry following Bruce protocol then performed CTP. For statistical analysis used the descriptive statistics, Pearson Correlation test, Student test. The Statistica 12 program used for the statistical test. **Results** The study included 38 participants included 19 (50 %) patients with positive stress induced myocardial perfusion defect on the CTP and 19 (50 %) with negative results. The mean age of the participants 58,77 years (std. div. ± 9,664). The bicycle ergometry specificity and sensitivity 61.11%, 57.89%, respectively. The diagnostic accuracy of the bicycle ergometry 59.46%. **Conclusions** The bicycle ergometry test characterized by severe limitations in terms of the IHD diagnosis. **Others** Recommended to combine additional diagnostic methods with the bicycle ergometry to improve it is diagnostic accuracy, such as single channel electrocardiography and exhaled breath analysis. Keywords * Ischemic heart disease * Bicycle Ergometry * Stress Computed Tomography Myocardial Perfusion Imaging * Diagnosis ## Introduction Ischemic heart disease (IHD) is one of the most common pathologies among the cardiovascular disease in terms of the mortality and morbidity [1]. This high prevalence of IHD in the community returns to the poor early detection and diagnostic methods of IHD. One of the most frequently used diagnostic method for individuals with clinical signs and symptoms of ischemic heart disease is the physical stress test, including bicycle ergometry [2]. The debate about the efficacy of this method is under evaluation since it is first use in clinical practice [3, 4]. However, this method is easy to use and safe as well as cost-effective. Therefore, this method is widespread as an elementary diagnostic method for IHD in compare to other expansive and invasive methods such as coronary angiography with Coronary Flow Reserve [5]. The current paper revises the specificity and sensitivity of the bicycle ergometry for usage as an elementary tool for IHD diagnosis through performing research on a participant with specific inclusion and exclusion criteria (published on the clinical trial ([NCT06181799](http://medrxiv.org/lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT06181799&atom=%2Fmedrxiv%2Fearly%2F2024%2F07%2F05%2F2024.07.03.24309879.atom)). ## Materials and methods A non-randomized, single center, mini-invasive, parallel, cross-sectional, diagnostic, observational, case-control prospective cohort study performed at the University Clinical Hospital-1. The data of this study extracted from another clinical trial performed by Marzoog, the full design of the study published on [clinicaltrials.gov](http://clinicaltrials.gov) ([NCT06181799](http://medrxiv.org/lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT06181799&atom=%2Fmedrxiv%2Fearly%2F2024%2F07%2F05%2F2024.07.03.24309879.atom)) [6]. The study approved by the Sechenov University, Russia, from “Ethics Committee Requirement № 19-23 from 26.10.2023”. The study included both males and females, and the age of the participants ≥ 40 years. The study participants passed exercise bicycle ergometry (on SCHILLER device; Bruce protocol) test to evaluate the response to physical activity. According to the results metabolic equivalent; Mets-BT (BT), the angina functional class (FC) in participants with positive physical stress test results determined, Where BT/Mets <50/<4 FC-III, BT/Mets 50-100/4-7 FC-II, BT/Mets >100/7 FC-I. During the bicycle ergometry, the participants monitored with 12-lead ECG and manual blood pressure measurement, 1 measured at the end of each 2 minute. The ergometry procedure discontinued if an increase in blood pressure ≥ 220 mmHg or horizontal or downsloping ST segment on the ECG ≥ 1 mm. Moreover, stop the procedure if the target heart rate (86% of the 220-age) is reached. To perform the stressed myocardial perfusion computer tomography imaging, all the participants present results of the venous creatinine level, eGFR (estimated glomerular filtration rate) according to the 2021 CKD-EPI Creatinine > 30 ml/min/1,73 m2, according to the recommendation for using this formula by the National kidney foundation and the American Society of Nephrology [7–10]. The participants got catheterization in the basilar vein or the radial vein for injection of contrast and Natrii adenosine triphosphate (10 mg/1ml) to induce pharmacological stress test to the heart by increasing heart rate. To prepare the Natrii adenosine triphosphate, an Adenosine triphosphate 3 ml dilute in 17 ml of Isotonic Sodium Chloride Solution 0.9%, the injected volume of the diluted drug in milliliters is calculated by body weight. For 1 dose, take 3 ml of adenosine triphosphate (3 ampoules of each 1 ml (10mg)) + 17 ml of isotonic solution of sodium chloride 0.9% in one syringe, 20 ml. For one patient, manually inject intravenously (IV) through the already inserted catheter at a rate of 300 μg/kg/2 minutes, depending on weight: 60 kg = 12 ml, 70 kg = 14 ml. 80 kg = 16 ml, 100 kg = 20 ml of the full dose. Computer tomography (Canon with 640 slice, 0,5mm thickness) with contrast (Omnipaque, 350-100ml), inject the contrast, then make rest image for myocardial perfusion, then wait 20 minutes and then inject the Natrii adenosine triphosphate intravenously (10 mg/1ml) according to the body weight to cause pharmacological stress test to the heart during two minutes in to the catheter. Then make the second image of the myocardial perfusion after stress test immediately. ## Results The descriptive statistic of the continuous variables demonstrated in table 1. View this table: [Table 1:](http://medrxiv.org/content/early/2024/07/05/2024.07.03.24309879/T1) Table 1: Descriptive statistics of the presented sample. The number of patients with normal body weight 17 (44.73684 %). overweight 15 (39.47368 %), and obesity first degree 6 (15.78947 %). The categorical variables are presented as a relative and absolute values in table 2 (A-W) View this table: [Table 2:](http://medrxiv.org/content/early/2024/07/05/2024.07.03.24309879/T2) Table 2: The table represents the categorical variables of the study in absolute and relative values. The results of the student test of the sample represented in table 3 (A-M). View this table: [Table 3:](http://medrxiv.org/content/early/2024/07/05/2024.07.03.24309879/T3) Table 3: The results of the student test of the sample represented. Only statistically significant difference represented in the table. Interestingly, the sensitivity and specificity of the bicycle ergometry showed a very low level and not sufficient for confirming the diagnosis of ischemic heart disease. (*Table 4*) View this table: [Table 4:](http://medrxiv.org/content/early/2024/07/05/2024.07.03.24309879/T4) Table 4: The specificity and sensitivity of the bicycle ergometry. (*) These values are dependent on disease prevalence. All the correlation results between the continuous variables presented in supplementary material. (Supplementary file 1 ## Dissuasion Interestingly, on the CTP test, 19 (50 %) participants with coronary artery atherosclerosis, 5 (26 %) of them with significant atherosclerosis (stenosis >60 %). Furthermore, out of the 19 patients with significant atherosclerosis of the coronary artery, 11 (57 %) had myocardial perfusion defect after stress test with ATP. Out of the 11 patients with positive myocardial perfusion defect after the stress test, 4 (36 %) participants with positive bicycle ergometry test. More interesting findings, in the whole sample there is 19 (50 %) participants with positive myocardial perfusion defect, and only 5 (26 %) of them with significant coronary artery stenosis. Out of the 19 positive myocardial perfusion defect, 11 (57 %) with positive/suspected results on the bicycle ergometry. 2 (5.26 %) participants out of the 38 with positive results on the bicycle ergometry with heart rate < 85 % of the required goal heart rate (220-age). In other participants with positive (11)/suspected (8) results on the bicycle ergometry with heart rate > 85 % of the required heart rate goal. In the whole sample there is 12 (31.58 %) positive, 9 (23.68 %) suspected, and 17 (44.47 %) negative on the bicycle ergometry. However, on the CTP, out of the 12 positive bicycle ergometry, only 5 (41.67 %) with positive myocardial perfusion defect after stress test with ATP. Moreover, out of the 9 suspected participants, 6 (66.67 %) had positive myocardial perfusion defect after stress test with ATP. The presented results showed that bicycle ergometry suffers from severe limitations in terms of specificity and sensitivity in the diagnosis of IHD. Additional methods are required to improve the diagnostic accuracy of the bicycle ergometry such as the exhaled breath analysis and single channel electrocardiography [11]. ## Conclusions On the light of the presented results, the diagnosis of IHD using bicycle ergometry independently is ultra extremely not sufficient and further investigations required to improve the diagnostic accuracy of the bicycle ergometry. As well as to innovate novel methods for early detection of IHD through the application of the current advances in technologies such as the use of artificial intelligence (machine learning models) in the interpretation of the electrocardiography monitoring for patient at home bases using their watches or phones [6, 12]. Additionally, supplementary methods can be combined with the bicycle ergometry to enhance it is diagnostic accuracy. ## Supporting information Supp. File 1. correlations [[supplements/309879_file02.xlsx]](pending:yes) ## Data Availability All data produced in the present work are contained in the manuscript ## Decelerations ### Ethics approval and consent to participate The study approved by the Sechenov University, Russia, from “Ethics Committee Requirement № 19-23 from 26.10.2023”. The study is under consideration by the [clinicaltrails.gov](http://clinicaltrails.gov) for registration. ### Consent for publication Written informed consent was obtained from the participants for publication of study results and any accompanying images. ### Availability of data and materials applicable on reasonable request. ### Competing interests The authors declare that they have no competing interests regarding publication. ### Funding’s The work of Philipp Kopylov and Peter Chomakhidze was financed by the government assignment 1023022600020-6 «Application of mass spectrometry and exhaled air emission spectrometry for cardiovascular risk stratification». ### Authors’ contributions **Basheer Abdullah Marzoog**, is the writer, researcher, collected and analyzed data, and revised the manuscript, **Peter Chomakhidze and Philipp Kopylov** revised the manuscript. All authors have read and approved the manuscript. ## Authors’ information **Basheer Abdullah Marzoog**, World-Class Research Center «Digital Biodesign and Personalized Healthcare», I.M. Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia; postal address: Russia, Moscow, 8-2 Trubetskaya street, 119991. (marzug{at}mail.ru, +79969602820). Scopus ID: 57486338800. **Peter Chomakhidze**, World-Class Research Center «Digital Biodesign and Personalized Healthcare», I.M. Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia; postal address: Russia, Moscow, 8-2 Trubetskaya street, 119991. Email: m.ba.m{at}bk.ru. **Philipp Kopylov**, World-Class Research Center «Digital Biodesign and Personalized Healthcare», I.M. Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia; postal address: Russia, Moscow, 8-2 Trubetskaya street, 119991. Email: kopylovf_yu{at}staff.sechenov.ru. The paper has not been submitted elsewhere ## Acknowledgments not applicable ## Footnotes * Competing interests: No competing interests regarding the publication. ## List of abbreviations IHD : Ischemic heart disease CTP : stress computed tomography myocardial perfusion imaging * Received July 3, 2024. * Revision received July 3, 2024. * Accepted July 5, 2024. * © 2024, Posted by Cold Spring Harbor Laboratory The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission. ## References 1. [1].Tsao, C. W.; Aday, A. W.; Almarzooq, Z. I.; Anderson, C. A. M.; Arora, P.; Avery, C. L.; Baker-Smith, C. M.; Beaton, A. Z.; Boehme, A. K.; Buxton, A. E.; et al. Heart Disease and Stroke Statistics - 2023 Update: A Report from the American Heart Association. Circulation, 2023, 147 (8), E93–E621. doi:10.1161/CIR.0000000000001123. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1161/CIR.0000000000001123&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=36695182&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F07%2F05%2F2024.07.03.24309879.atom) 2. [2].Yeates, K.; Lohfeld, L.; Sleeth, J.; Morales, F.; Rajkotia, Y.; Ogedegbe, O. A Global Perspective on Cardiovascular Disease in Vulnerable Populations. Can. J. Cardiol., 2015, 31 (9), 1081–1093. doi:10.1016/j.cjca.2015.06.035. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.cjca.2015.06.035&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=26321432&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F07%2F05%2F2024.07.03.24309879.atom) 3. [3].Ofori, E. K.; Frimpong, E.; Ademiluyi, A.; Olawale, O. A. Ergometer Cycling Improves the Ambulatory Function and Cardiovascular Fitness of Stroke Patients—a Randomized Controlled Trial. J. Phys. Ther. Sci., 2019, 31 (3), 211–216. doi:10.1589/jpts.28.211. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1589/jpts.28.211&link_type=DOI) 4. [4].Myers, J.; Arena, R.; Franklin, B.; Pina, I.; Kraus, W. E.; McInnis, K.; Balady, G. J. Recommendations for Clinical Exercise Laboratories. Circulation, 2009, 119 (24), 3144–3161. doi:10.1161/CIRCULATIONAHA.109.192520. [FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiRlVMTCI7czoxMToiam91cm5hbENvZGUiO3M6MTQ6ImNpcmN1bGF0aW9uYWhhIjtzOjU6InJlc2lkIjtzOjExOiIxMTkvMjQvMzE0NCI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDI0LzA3LzA1LzIwMjQuMDcuMDMuMjQzMDk4NzkuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 5. [5].van der Wall, E. E. Alternative Stress Methods in the Evaluation of Coronary Artery Disease. In Nuclear Cardiology and Cardiac Magnetic Resonance; Springer Netherlands: Dordrecht, 1992; pp 199–214. doi:10.1007/978-94-011-2826-1_11. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/978-94-011-2826-1_11&link_type=DOI) 6. [6].Marzoog, B. A.; Chomakhidze, P.; Kopylov, P. The Biomarkers of Exhaled Breath & Single Channel Electrocardiography in the Diagnosis of Ischemic Heart Disease. New Emirates Med. J., 2024. 7. [7].Cockcroft, D. W.; Gault, M. H. Prediction of Creatinine Clearance from Serum Creatinine. Nephron, 1976, 16 (1), 31–41. doi:10.1159/000180580. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1159/000180580&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=1244564&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F07%2F05%2F2024.07.03.24309879.atom) [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=A1976AV14200003&link_type=ISI) 8. [8].Winter, M. A.; Guhr, K. N.; Berg, G. M. Impact of Various Body Weights and Serum Creatinine Concentrations on the Bias and Accuracy of the Cockcroft-Gault Equation. Pharmacotherapy, 2012, 32 (7), 604–612. doi:10.1002/j.1875-9114.2012.01098.x. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/j.1875-9114.2012.01098.x&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=22576791&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F07%2F05%2F2024.07.03.24309879.atom) 9. [9].Brown, D. L.; Masselink, A. J.; Lalla, C. D. Functional Range of Creatinine Clearance for Renal Drug Dosing: A Practical Solution to the Controversy of Which Weight to Use in the Cockcroft-Gault Equation. Ann. Pharmacother., 2013, 47 (7–8), 1039–1044. doi:10.1345/aph.1S176. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1345/aph.1S176&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=23757387&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F07%2F05%2F2024.07.03.24309879.atom) 10. [10].Delgado, C.; Baweja, M.; Crews, D. C.; Eneanya, N. D.; Gadegbeku, C. A.; Inker, L. A.; Mendu, M. L.; Miller, W. G.; Moxey-Mims, M. M.; Roberts, G. V.; et al. A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. Am. J. Kidney Dis., 2022, 79 (2), 268-288.e1. doi:10.1053/j.ajkd.2021.08.003. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1053/j.ajkd.2021.08.003&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=34563581&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F07%2F05%2F2024.07.03.24309879.atom) 11. [11].Marzoog, B. A. Breathomics Detect the Cardiovascular Disease: Delusion or Dilution of the Metabolomic Signature. Curr. Cardiol. Rev., 2024, 20. doi:10.2174/011573403X283768240124065853. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.2174/011573403X283768240124065853&link_type=DOI) 12. [12].Marzoog, B. A.; Averina, D. Nicotinamide Mononucleotide in the Context of Myocardiocyte Longevity. Curr. Aging Sci., 2023, 17. doi:10.2174/0118746098266041231212105020. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.2174/0118746098266041231212105020&link_type=DOI)